FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036288045> ?p ?o ?g. }

• W3036288045 endingPage "4550" @default.
• W3036288045 startingPage "4542" @default.
• W3036288045 abstract "Abstract Purpose: This phase II study (NCT03469557) assessed safety/tolerability and antitumor activity of first-line tislelizumab, a monoclonal antibody against programmed cell death-1, plus chemotherapy in patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) or gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Patients and Methods: Patients with ESCC received tislelizumab [200 mg i.v. every 3 weeks (Q3W)] plus cisplatin (80 mg/m² i.v. Q3W for ≤6 cycles) and fluorouracil (800 mg/m²/day i.v., Days 1–5 Q3W for ≤6 cycles); patients with G/GEJ adenocarcinoma received tislelizumab (200 mg i.v. Q3W) plus oxaliplatin (130 mg/m² i.v. Q3W for up to six cycles) and oral capecitabine (1,000 mg/m² twice daily, Days 1–14 Q3W). The safety/tolerability profile of combination therapy was the primary endpoint; secondary endpoints included objective response rate (ORR), duration of response (DoR), disease control rate (DCR), and progression-free survival per RECIST v1.1. Exploratory endpoints included overall survival and potential predictive biomarkers. Results: As of March 31, 2019, 30 patients (n = 15 per cohort) were enrolled. Most common adverse events considered related to tislelizumab and/or chemotherapy were anemia (n = 18), decreased appetite (n = 17), nausea (n = 16), and asthenia (n = 15). One patient experienced fatal hepatic dysfunction, confounded by progressive disease and underlying hepatitis, attributed to treatment by the investigator. Confirmed ORRs and DCRs were 46.7% and 80%, respectively, for both ESCC and G/GEJ adenocarcinoma. In ESCC, median DoR was 12.8 months (95% confidence interval, 3.5–12.8); DoR was not yet mature for the G/GEJ cohort. Conclusions: Tislelizumab plus chemotherapy demonstrated durable responses with manageable tolerability in patients with advanced ESCC or G/GEJ adenocarcinoma." @default.
• W3036288045 created "2020-06-25" @default.
• W3036288045 creator A5004295637 @default.
• W3036288045 creator A5006822602 @default.
• W3036288045 creator A5016729352 @default.
• W3036288045 creator A5025681830 @default.
• W3036288045 creator A5044825014 @default.
• W3036288045 creator A5062179244 @default.
• W3036288045 creator A5066182565 @default.
• W3036288045 creator A5070745750 @default.
• W3036288045 creator A5087661837 @default.
• W3036288045 date "2020-09-01" @default.
• W3036288045 modified "2023-10-12" @default.
• W3036288045 title "Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma" @default.
• W3036288045 cites W1971821333 @default.
• W3036288045 cites W2007093497 @default.
• W3036288045 cites W2074546881 @default.
• W3036288045 cites W2100439220 @default.
• W3036288045 cites W2104350866 @default.
• W3036288045 cites W2104759721 @default.
• W3036288045 cites W2107554910 @default.
• W3036288045 cites W2108661938 @default.
• W3036288045 cites W2116435502 @default.
• W3036288045 cites W2135708326 @default.
• W3036288045 cites W2143278325 @default.
• W3036288045 cites W2147592245 @default.
• W3036288045 cites W2150024391 @default.
• W3036288045 cites W2155167083 @default.
• W3036288045 cites W2210453860 @default.
• W3036288045 cites W2223406810 @default.
• W3036288045 cites W2563470051 @default.
• W3036288045 cites W2601596971 @default.
• W3036288045 cites W2604488831 @default.
• W3036288045 cites W2774422690 @default.
• W3036288045 cites W2776744188 @default.
• W3036288045 cites W2787968488 @default.
• W3036288045 cites W2799565954 @default.
• W3036288045 cites W2884949281 @default.
• W3036288045 cites W2889646458 @default.
• W3036288045 cites W2934520391 @default.
• W3036288045 cites W2947475298 @default.
• W3036288045 cites W2948169107 @default.
• W3036288045 cites W2979211828 @default.
• W3036288045 cites W3036157555 @default.
• W3036288045 cites W951317561 @default.
• W3036288045 doi "https://doi.org/10.1158/1078-0432.ccr-19-3561" @default.
• W3036288045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32561664" @default.
• W3036288045 hasPublicationYear "2020" @default.
• W3036288045 type Work @default.
• W3036288045 sameAs 3036288045 @default.
• W3036288045 citedByCount "54" @default.
• W3036288045 countsByYear W30362880452020 @default.
• W3036288045 countsByYear W30362880452021 @default.
• W3036288045 countsByYear W30362880452022 @default.
• W3036288045 countsByYear W30362880452023 @default.
• W3036288045 crossrefType "journal-article" @default.
• W3036288045 hasAuthorship W3036288045A5004295637 @default.
• W3036288045 hasAuthorship W3036288045A5006822602 @default.
• W3036288045 hasAuthorship W3036288045A5016729352 @default.
• W3036288045 hasAuthorship W3036288045A5025681830 @default.
• W3036288045 hasAuthorship W3036288045A5044825014 @default.
• W3036288045 hasAuthorship W3036288045A5062179244 @default.
• W3036288045 hasAuthorship W3036288045A5066182565 @default.
• W3036288045 hasAuthorship W3036288045A5070745750 @default.
• W3036288045 hasAuthorship W3036288045A5087661837 @default.
• W3036288045 hasBestOaLocation W30362880451 @default.
• W3036288045 hasConcept C121608353 @default.
• W3036288045 hasConcept C126322002 @default.
• W3036288045 hasConcept C141071460 @default.
• W3036288045 hasConcept C143998085 @default.
• W3036288045 hasConcept C197934379 @default.
• W3036288045 hasConcept C203092338 @default.
• W3036288045 hasConcept C2776694085 @default.
• W3036288045 hasConcept C2777909004 @default.
• W3036288045 hasConcept C2778375690 @default.
• W3036288045 hasConcept C2781182431 @default.
• W3036288045 hasConcept C526805850 @default.
• W3036288045 hasConcept C535046627 @default.
• W3036288045 hasConcept C71924100 @default.
• W3036288045 hasConcept C90924648 @default.
• W3036288045 hasConceptScore W3036288045C121608353 @default.
• W3036288045 hasConceptScore W3036288045C126322002 @default.
• W3036288045 hasConceptScore W3036288045C141071460 @default.
• W3036288045 hasConceptScore W3036288045C143998085 @default.
• W3036288045 hasConceptScore W3036288045C197934379 @default.
• W3036288045 hasConceptScore W3036288045C203092338 @default.
• W3036288045 hasConceptScore W3036288045C2776694085 @default.
• W3036288045 hasConceptScore W3036288045C2777909004 @default.
• W3036288045 hasConceptScore W3036288045C2778375690 @default.
• W3036288045 hasConceptScore W3036288045C2781182431 @default.
• W3036288045 hasConceptScore W3036288045C526805850 @default.
• W3036288045 hasConceptScore W3036288045C535046627 @default.
• W3036288045 hasConceptScore W3036288045C71924100 @default.
• W3036288045 hasConceptScore W3036288045C90924648 @default.
• W3036288045 hasIssue "17" @default.
• W3036288045 hasLocation W30362880451 @default.
• W3036288045 hasOpenAccess W3036288045 @default.
• W3036288045 hasPrimaryLocation W30362880451 @default.

• next